Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | CDK9 | P50750 | 12/20 | 0.42 |
| ▸ | CDC7 | O00311 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.42 |
| ▸ | CCNT1 | O60563 | 10/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | NMT1 | P30419 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | CCNK | O75909 | 1/20 | 0.37 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26686419 | 0.93 | CDK9 (0.44) | HRH3CDK9CDC7PIM1CCNT1 | |
| SCHEMBL26686430 | 0.87 | CDK9 (0.37) | CDK9CDC7PIM1CCNT1CCNK | |
| SCHEMBL26686782 | 0.85 | CDK9 (0.45) | HRH3CDK9CDC7PIM1CCNT1 | |
| SCHEMBL26686140 | 0.81 | DAO (0.39) | CDK9CDC7PIM1CCNKCDK12 | |
| SCHEMBL26686492 | 0.73 | KDM5B (0.46) | CDK9CDC7PIM1 | |
| SCHEMBL25427476 | 0.72 | CDK9 (0.63) | CDK9CCNT1 | |
| SCHEMBL31380026 | 0.72 | CDK9 (0.63) | CDK9CCNT1 | |
| SCHEMBL26889438 | 0.72 | HRH3 (0.44) | HRH3CDK9CDC7PIM1 | |
| SCHEMBL26686463 | 0.71 | CDK9 (0.42) | CDK9CDC7PIM1CCNT1CCNK | |
| SCHEMBL20839836 | 0.70 | CCNK (0.40) | CCNKCDK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304576-A1 | IKK INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2025-10-02 | — | — | US | disclosed |
| EP-4522597-A1 | IKK INHIBITORS | Cancer Research Technology Limited (GB) | 2025-03-19 | — | — | EP | disclosed |
| CN-119562945-A | IKK inhibitors | 癌症研究技术有限公司 | 2025-03-04 | — | — | CN | disclosed |
| WO-2023218201-A1 | IKK INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304576-A1 | IKK INHIBITORS | NFKBIA, IKBKE, IKBKB | HRH3 3648/4885CDK9 98/4885CDC7 436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.